Compare Tripadvisor Inc Common Stock (TRIP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tripadvisor Inc Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Tripadvisor Inc Common Stock trades at $8.94 (market cap $1.01B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 126.3× Tripadvisor Inc Common Stock's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tripadvisor Inc Common Stock for 57 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TRIP | VRTX | |
|---|---|---|
Market Cap | $1.01B | $127.55B |
Volume | 3,004,748 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $16.72 | $557.96 |
52-Week Low | $8.04 | $407.37 |
Typical Hold Time | 57 Days | 120 Days |
Enterprise Value | $1.06B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TripAdvisor (TRIP) trades at $8.63, up 1.29% on the day but near its 52-week low of $8.27. The stock is technically bearish, with recent earnings misses and a net cash outflow of $29M in 2025. Revenue grew to $1.89B in 2025, but net margins remain thin at 0.27%. Analyst sentiment is mixed, with a consensus price target of $13.58 but a majority hold rating.
The outlook is cautious. Upside potential exists if the Viator segment recovers and TheFork sale concludes, but risks include persistent earnings volatility, competitive pressure from AI travel tools, and weak cash flow trends. The stock offers value on P/S (0.57) but requires improved execution to justify higher multiples.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
